Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Device Center Gets $239 Million For Fiscal 2008

This article was originally published in The Gray Sheet

Executive Summary

CDRH will get $239.67 million from Congress to spend for the balance of fiscal year 2008 - $19 million more than in fiscal 2007. The funding was approved as part of an omnibus appropriations package signed by President Bush Dec. 26

You may also be interested in...



FY 2009 FDA Appropriations Will Likely Have To Wait For Next Administration

House Democratic leaders are signaling an intention to put off finalizing fiscal year 2009 appropriations at least until next March, charging Republican members of Congress and the Bush administration with standing in the way of negotiating mutually agreeable bills

FY 2009 FDA Appropriations Will Likely Have To Wait For Next Administration

House Democratic leaders are signaling an intention to put off finalizing fiscal year 2009 appropriations at least until next March, charging Republican members of Congress and the Bush administration with standing in the way of negotiating mutually agreeable bills

FDA Scientific Capacity Inadequate; New Device Technology At Risk

CDRH is not equipped to understand the science behind many cutting-edge device technologies, says a Nov. 29 report from the Subcommittee on Science and Technology, an ad hoc panel of the FDA Science Board

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025623

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel